Abstract：Objective: To compare the application effects of protein succinylate iron oral solution combined with rosuvastatin or combined with recombinant human erythropoietin (rhEPO) in non-dialysis renal anemia patients. Methods: A total of 120 inpatient and outpatient non-dialysis renal anemia patients admitted to our hospital from April 2020 to October 2022 were selected and divided into two groups using a simple randomization method. The control group was treated with protein succinylate iron oral solution combined with rhEPO, while the observation group was treated with protein succinylate iron oral solution combined with rosuvastatin. Differences in renal function indicators, anemia indicators, and iron metabolism indicators between the two groups were examined, and the incidence of adverse reactions was recorded. Results: There was no significant difference in renal function related factors between the two groups before and after treatment (P>0.05). There was no significant difference in renal function index between observation group and control group before and after treatment (P>0.05).There was no significant difference in anemia-related indicators between the two groups before treatment (P>0.05). Compared with before treatment, hemoglobin (Hb) and erythrocyte specific volume (HCT) of the two groups were increased after treatment, and the difference of Hb and HCT before and after treatment of the observation group was greater than that of the control group (P<0.05), and the immature reticulum ratio (IRF) between the two groups before and after treatment had no significant difference (P>0.05). There was no significant difference in iron metabolism between the two groups before treatment (P>0.05). Compared with the control group before treatment, the saturation of ferritin and transferrin in the two groups increased after treatment, and the total iron binding capacity decreased after treatment. The difference of iron metabolism indexes in the observation group before and after treatment was greater than that in the control group (P<0.05). The cumulative incidence of adverse reactions in the observation group was 11.67% (7/60) compared with 10.00% (6/60) in the control group, with no significant difference (P>0.05). Conclusion: The treatment of non-dialysis renal anemia with protein succinylate iron oral solution combined with rosuvastatin shows better improvement in anemia and iron metabolism indicators than the combination with rhEPO. At the same time, it ensures safety and is worthy of clinical recommendation.
宋大莉, 袁玲, 王晓娟, 齐金秋. 蛋白琥珀酸铁口服溶液联合罗沙司他或rhEPO在非透析肾性贫血患者中的应用比较[J]. 河北医学, 2023, 29(12): 2087-2092.
SONG Dali, YUAN Ling, WANG Xiaojuan, et al. Comparison of the Application of Protein Succinylate Iron Oral Solution Combined with Rosuvastatin or rhEPO in Non-Dialysis Renal Anemia Patients. HeBei Med, 2023, 29(12): 2087-2092.
2023, Vol. 29 
冀公网安备13080202000677号